Invivyd (NASDAQ:IVVD) Trading 6.1% Higher – Time to Buy?

Shares of Invivyd, Inc. (NASDAQ:IVVD) rose 6.1% during trading on Tuesday . The stock traded as high as $2.34 and last traded at $2.3550. Approximately 1,923,221 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 7,673,814 shares. The stock had previously closed at $2.22.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. D Boral Capital cut Invivyd from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. HC Wainwright upped their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 8th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.33.

Invivyd Trading Up 7.4%

The business’s fifty day moving average price is $2.05 and its 200-day moving average price is $1.30. The company has a market capitalization of $555.99 million, a P/E ratio of -5.07 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $13.13 million during the quarter, compared to analysts’ expectations of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. As a group, equities research analysts forecast that Invivyd, Inc. will post -1.64 EPS for the current year.

Insider Activity at Invivyd

In other Invivyd news, Director Kevin F. Mclaughlin bought 50,000 shares of Invivyd stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average price of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director owned 50,000 shares in the company, valued at approximately $125,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

Several institutional investors have recently added to or reduced their stakes in the business. Catalyst Funds Management Pty Ltd purchased a new stake in Invivyd during the 2nd quarter valued at about $27,000. Nuveen LLC purchased a new position in Invivyd in the 1st quarter worth approximately $65,000. Vanguard Personalized Indexing Management LLC lifted its position in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Invivyd in the third quarter worth approximately $109,000. Finally, RA Capital Management L.P. bought a new stake in Invivyd during the 3rd quarter valued at $18,831,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.